Deafness and Blindness clinical trials at UCSF

1 research study open to eligible people

Deafness is loss of hearing and blindness is loss of sight. UCSF is studying a drug called ultevursen for people with retinitis pigmentosa linked to a change in the USH2A gene. UCSF is testing the drug in a Phase 2b study to check its safety and tolerability.

Showing trials for

  • Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

    open to eligible people ages 8 years and up

    The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.

    San Francisco, California and other locations

Last updated: